[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"trichuris-trichiura-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:trichuris-trichiura-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100577588","phase-3-efficacy-and-safety-of-emodepside-in-participants-with-soil-transmitted-helminth-infections-100577588",false,"NCT06800248","Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections","A Phase III Single-center, Randomized, Double-Blinded, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of Emodepside Compared to Multiple Doses of Mebendazole in Adolescent and Adult Participants With Soil-transmitted Helminthiasis","TREMO-Siargao","Inclusion Criteria:\n\n1. Male or non-pregnant (confirmed by a negative serum pregnancy test) and non-breastfeeding female participants aged 12 years and older.\n2. T. trichiura as a single infection or co-infection with hookworm and\u002For A. lumbricoides, confirmed by presence of T. trichiura eggs assessed by Kato-Katz thick smears from two stool samples (infection intensity defined as number of eggs per gram of stool (EPG): (1) light (1-999 EPG), (2) moderate to heavy (≥1000 EPG).\n3. A minimum infection intensity of 24 eggs per gram of stool at baseline and at least two positive slides out of the four slides assessed at baseline.\n4. Written informed consent signed by the participant and\u002For legally authorized representative(s) according to the participant's age as established per local regulations. In addition, participant's assent is required as applicable by local laws and regulations for adolescents of 12-17 years of age.\n5. Women of childbearing potential must agree to use an effective, culturally appropriate contraceptive measure from at least 28 days prior to first dosage for hormonal contraceptives only and for non-hormonal contraceptive measures from screening Visit 2 until End of Study Visit.\n\nExclusion Criteria:\n\n1. Presence of any systemic illnesses, renal and\u002For hepatic impairment, any other acute or chronic health conditions or congenital disorders which, in the opinion of the Investigator, would make the participant unsuitable for participation in a clinical study or may interfere with the efficacy, safety, and\u002For pharmacokinetic (PK) evaluation of the study drug.\n2. Any of the following:\n\n   1. Platelet \\\u003C75,000\u002Fmm3\n   2. Alanine Aminotransferase (ALT) or Serum Glutamic Pyruvic Transaminase (SGPT) \\>3x upper limit of normal (ULN)\n   3. Total bilirubin \\>2xULN\n   4. Estimated Glomerular Filtration Rate (eGFR) \\\u003C90 ml\u002Fmin\u002F1.73 m2 (adolescents) or estimated creatinine clearance (CrCl) \\\u003C90 ml\u002F min (adults)\n3. Treatment with the following anthelminthic drugs: albendazole, mebendazole, ivermectin, within 28 days before the first dose of study intervention or planned before End of Study Visit.\n4. Use of sensitive CYP3A4 substrates within 14 days before the start of the first study intervention and until at least 14 days after the last administration of study intervention.\n5. Treatment with metronidazole within 2 days before the first dose of study intervention or planned before 24 hours after last administration of study intervention.\n6. Previous assignment to a study intervention for another study planned to be administered during the period the participant is enrolled in this study (from date of informed consent to last follow-up).\n7. Known allergy\u002Fhypersensitivity to mebendazole and\u002For emodepside","ALL","12 Years",{"count":20,"type":21},315,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study aims to assess the efficacy and safety of emodepside compared to mebendazole in adults and adolescents infected with T. trichiura, either as single infection or co-infections with hookworm and\u002For A. lumbricoides.",[27,28,29],"Trichuris Trichiura; Infection","Hookworm Infection","Ascaris Lumbricoides Infection",[31,32,33,34,35,36,37,38,39,40,41],"Trichuris trichiura","Ascaris lumbricoides","STH","Efficacy","Safety","Hookworm","Emodepside","Soil-transmitted helminths","Roundworm","Whipworm","Mebendazole","NOT_YET_RECRUITING","2026-06-10",{"date":45,"type":46},"2026-06-11","ACTUAL",{"date":48,"type":21},"2026-09",{"date":50,"type":21},"2027-08",{"name":52,"class":53},"Swiss Tropical & Public Health Institute","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":17,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":22,"phases":67,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":54},"100604147","phase-4-moxidectin-versus-ivermectin-as-mass-drug-administration-for-the-control-of-onchocerciasis-and-other-neglected-tropical-diseases-100604147","NCT07145736","Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases","Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases: A Cluster-randomised Trial","EKAIO","Inclusion Criteria:\n\n* Male or female children and adults\n* Residents in the villages selected for MDA treatment\n\nExclusion Criteria:\n\n* Arm 1 (ivermectin): children under the age of 5 and\u002For under 90 cm of height\n* Arm 2 (moxidectin): children under the age of 12 years (who will receive ivermectin if they are at least 90 cm in height\u002F5 years of age and above).\n* Arm 1 (ivermectin): Women breast-feeding babies under 45 days of age\n* Arm 2 (moxidectin): All breastfeeding women (who will be offered ivermectin if their infants is at least 45 days old)\n* Know allergy to ivermectin or moxidectin\n* Attending other clinical trials during the study\n* Pregnant\n* Arm 2 (moxidectin): Women planning to become pregnant in the 3 months post-treatment\n* Refusal to receive one or both study drugs, i.e. participants in villages allocated to receive moxidectin who refuse to receive moxidectin will be given the option to receive ivermectin; if they refuse to receive both drugs they will be excluded from the MDA altogether\n* Has an illness that makes them too sick or weak to get out of bed\n* Currently hospitalized",true,"5 Years",{"count":66,"type":21},52000,[68],"PHASE4","This clinical trial compares two treatments - ivermectin and moxidectin - to learn which is better at reducing the proportion of people with onchocerciasis (river blindness) when given through mass drug administration (MDA) in Angola. Both drugs are approved by the United States Food and Drug Administration (FDA) to treat this disease. The study also explores how these treatments affect other infections common in the region, including intestinal worms (soil-transmitted helminths) and scabies.\n\nThe trial aims to answer the following key questions:\n\n* How do moxidectin and ivermectin compare in reducing the prevalence (how common the disease is) and intensity (amount of parasites per person) of onchocerciasis in the community?\n* Do the treatments differ in their effect on the prevalence and intensity of soil-transmitted helminths and the prevalence of scabies?\n* Does moxidectin reduce transmission of onchocerciasis more effectively than ivermectin, based on genetic testing of parasites in people and lab testing of the blackflies that carry the infection?\n* How many more years of treatment would be needed to reach elimination with each drug, based on mathematical disease modelling?\n* How do communities feel about receiving moxidectin versus ivermectin, and what factors help or make it harder to carry out MDA programs with moxidectin versus ivermectin?\n\nThe study takes place in Bié Province, Angola, and involves 20 groups of villages randomly assigned to receive either moxidectin or ivermectin once a year for four years. Prior to every round of MDA, researchers will collect skin, stool and blood samples from a sample of the people living in the study area. We believe the results will help guide global policy on the use of moxidectin in efforts to eliminate onchocerciasis and control related diseases.",[71,29,27,72,73],"Onchocerciasis","Hookworm Infections","Scabies","RECRUITING","2025-11-18",{"date":77,"type":46},"2025-11-21",{"date":79,"type":46},"2025-08-04",{"date":81,"type":21},"2029-06-30",{"name":83,"class":84},"Kirby Institute","OTHER_GOV"]